Preclinical study finds antitumor effects of bispecific antibody

October 5, 2017, Chugai Pharmaceutical

Chugai Pharmaceutical announced today that the preclinical study findings on its original bispecific antibody ERY974, a molecule that binds Glypican-3 and CD3 simultaneously, and that is currently under development as a Phase I clinical study for solid tumors, were published in the online edition of Science Translational Medicine on October 4, 2017.

"ERY974 is a bispecific antibody created under the joint research between Chugai and Chugai Pharmabody Research with the application of Chugai's proprietary innovative antibody engineering technologies. We are extremely pleased that our research findings on ERY974 have been published in Science Translational Medicine," said Dr. Hisafumi Okabe, senior vice president for research and translational clinical research. "It is said that has made a paradigm shift in cancer treatment and that the role of the immune system in cancer treatment is likely to continue to grow in the future. As a cancer immunotherapy, we have high hopes that ERY974 will demonstrate anti-tumor effects in future clinical studies and become a drug that can contribute to the treatment of patients."

Glypican-3 (GPC3) is a membrane protein that is expressed with high frequency on the cellular membranes of various tumor cells including , , and gastric cancer. GPC3 is reported to be expressed in various tissues in the fetal stage and play an important role, but is rarely expressed in normal adult tissues. As GPC3 expression is observed through the malignant transformation of cells, GPC3 is thought to be a protein specific to cancer (tumor-associated antigen).

ERY974 is a bispecific antibody that binds to both GPC3 on the cancer cell membrane and to CD3, a membrane protein expressed on T cells, a type of lymphocyte. ERY974 is a T cell Redirecting AntiBody (TRAB) created with Chugai's proprietary antibody engineering technology, and while simultaneously binding to GPC3 and CD3 and directing T cells to , it also activates T cells, specifically attacking and killing neighboring cancer cells. Based on this mechanism whereby it activates T cells and attacks cancer cells, TRAB is classified as a type of cancer immunotherapy.

The following points were shown in this research:

  • According to the immunohistochemistry, GPC3 is expressed in various cancers (a hepatocellular carcinoma, a squamous lung cancer, a small cell lung cancer, an esophageal cancer, a gastric cancer and a head and neck cancer), and as previously reported, it is rarely expressed in normal tissues (30 different tissues) (in vitro)
  • GPC3-dependent T cell activation and killing of cancer by ERY974 was observed in vitro
  • In three different experimental tumor models using mouse, ERY974 demonstrated anti-tumor effects
  • Anti-tumor effects were observed even in cancers where other immunotherapies are ineffective (Mouse)
  • Tolerability of ERY974 was observed in toxicity testing in animal

Based on the results of this preclinical study, Chugai began phase I clinical trial of ERY974 in patients with GPC3 positive solid tumors in the United States in August 2016 (NCT02748837).

Explore further: Special T cells that target solid tumors offer potential treatment for pediatric and adult cancers

More information: Takahiro Ishiguro et al. An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors, Science Translational Medicine (2017). DOI: 10.1126/scitranslmed.aal4291 Daniel Baumhoer et al.

Glypican 3 Expression in Human Nonneoplastic, Preneoplastic, and Neoplastic Tissues, American Journal of Clinical Pathology (2008). DOI: 10.1309/HCQWPWD50XHD2DW6

Related Stories

Special T cells that target solid tumors offer potential treatment for pediatric and adult cancers

September 14, 2016
Adoptive cell-therapies, in which a patient's own immune cells are used to recognize and target tumors, have shown breakthrough results for patients with certain B-cell malignancies, or cancers of the blood, but this therapy ...

Immunotherapy could help tackle tough liver cancer

April 11, 2014
Significant new data presented today at the International Liver Congress 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy.

New chimeric antibody that suppresses malignant cancers in dogs

August 25, 2017
Similar to humans, dogs live longer than before and an increasing number of them die from cancer. As seen in humans, dogs have malignant cancers that cannot be treated by existing therapies such as surgery, radiotherapy and ...

New study offers novel treatment strategy for patients with colon cancer

September 20, 2017
Colorectal cancer is the fourth leading cause of cancer-related deaths worldwide.

Glypican-3 gene function in regulating body size helps inform novel cancer treatments

May 12, 2008
In a leading study that has implications for the development of novel therapies for a number of breast, lung and ovarian cancers that have lost the expression of a gene called glypican-3 (GPC3), Sunnybrook researchers have ...

A new role of glypican-3 in hepatocellular carcinoma

August 2, 2010
A study group from Japan analyzed the association of glypican-3 (GPC3) expression with Wnt and other growth signaling molecules in hepatocellular carcinoma (HCC). They found altered expressions of various matrix metalloproteinases ...

Recommended for you

RNA thought to spread cancer shows ability to suppress breast cancer metastasis

October 22, 2018
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a form of RNA called metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) appears to suppress breast cancer metastasis in mice, ...

Revealing the molecular mystery of human liver cells

October 22, 2018
A map of the cells in the human liver has been created by University Health Network Transplant Program and University of Toronto researchers, revealing for the first time differences between individual cells at the molecular ...

Targeting a hunger hormone to treat obesity

October 22, 2018
About 64 per cent of Canadian adults are overweight or obese, according to Health Canada. That's a problem, because obesity promotes the emergence of chronic diseases such as type 2 diabetes, heart disease and some cancers.

New tool gives deeper understanding of glioblastoma

October 22, 2018
Researchers in the lab of Charles Danko at the Baker Institute for Animal Health have developed a new tool to study genetic "switches" active in glioblastoma tumors that drive growth of the cancer. In a new paper in Nature ...

Pancreatic cancer genetic marker may predict outcomes with radiation therapy

October 22, 2018
Pancreatic cancer is one of the most difficult cancers to treat and is a leading cause of cancer-related deaths. Now, Sidney Kimmel Cancer Center—Jefferson Health and Lankenau Institute for Medical Research scientists find ...

New drug combination destroys chemo-resistant blood cancer

October 22, 2018
Researchers from The Ottawa Hospital and the University of Ottawa have developed a promising targeted strategy to treat chemotherapy-resistant acute myeloid leukemia (AML) and a diagnostic test to determine which AML patients ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.